Nuvation Bio (Q3 2025) delivered significantly improved top-line results driven by the U.S. launch of IBTROZI (starting June 2025) and Japan approval in September 2025. Total 9-month revenue surged to $21.0M (vs. $2.2M in 2024), resulting in a Gross Profit of $13.0M. Consequently, the Net Loss narrowed substantially to \((\\)168.0M)\( from \)($518.5M)\( the prior year (the prior period was heavily impacted by the \\)425.1M IPR&D charge from the April 2024 AnHeart acquisition).
Liquidity was bolstered by securing up to $250M in non-dilutive financing from Sagard following IBTROZI FDA approval,
...